2023 Q3 Form 10-Q Financial Statement

#000095017023042476 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $2.000K $863.0K
YoY Change -100.0% -99.77% -95.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.77M $8.953M $8.410M
YoY Change 56.79% 6.46% -62.98%
% of Gross Profit
Research & Development $10.55M $5.983M $5.904M
YoY Change 81.22% 1.34% -55.94%
% of Gross Profit
Depreciation & Amortization $100.0K $200.0K $200.0K
YoY Change -50.0% 0.0% -60.0%
% of Gross Profit
Operating Expenses $23.32M $14.94M $14.31M
YoY Change 66.97% 4.35% -60.37%
Operating Profit -$23.32M -$14.93M -$14.21M
YoY Change 67.93% 5.1% -60.14%
Interest Expense $2.592M $2.703M $2.772M
YoY Change -6.53% -2.49% -20.85%
% of Operating Profit
Other Income/Expense, Net -$52.11M -$5.000K $5.735M
YoY Change 52008.0% -100.09% 97.69%
Pretax Income -$73.45M -$17.80M -$6.834M
YoY Change 399.14% 160.51% -83.49%
Income Tax $1.000K $4.000K -$837.0K
% Of Pretax Income
Net Earnings -$73.45M -$17.81M -$5.513M
YoY Change 1336.33% 223.0% -92.98%
Net Earnings / Revenue -890350.0% -638.82%
Basic Earnings Per Share -$4.89 -$1.47 -$0.75
Diluted Earnings Per Share -$4.89 -$1.47 -$29.90K
COMMON SHARES
Basic Shares Outstanding 13.88M 11.86M 184.2M
Diluted Shares Outstanding 15.02M 12.14M 7.375M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.60M $26.45M $48.51M
YoY Change -66.0% -45.47% -26.5%
Cash & Equivalents $7.800M $22.70M $48.50M
Short-Term Investments
Other Short-Term Assets $172.0K $193.0K $1.060M
YoY Change -78.45% -81.79% 96.66%
Inventory
Prepaid Expenses $3.179M $3.912M $7.615M
Receivables $0.00
Other Receivables $817.0K
Total Short-Term Assets $19.25M $33.89M $60.15M
YoY Change -58.48% -43.66% -47.39%
LONG-TERM ASSETS
Property, Plant & Equipment $1.236M $1.351M $2.454M
YoY Change -41.48% -44.95% -55.17%
Goodwill $6.072M $6.072M $6.072M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $6.000M $6.000M $6.000M
YoY Change 0.0% 0.0%
Other Assets $6.314M $6.478M $6.227M
YoY Change 1.4% 4.03% 4165.07%
Total Long-Term Assets $15.46M $15.79M $16.96M
YoY Change -4.91% -6.89% 201.71%
TOTAL ASSETS
Total Short-Term Assets $19.25M $33.89M $60.15M
Total Long-Term Assets $15.46M $15.79M $16.96M
Total Assets $34.70M $49.67M $77.10M
YoY Change -44.58% -35.57% -35.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.905M $5.042M $4.315M
YoY Change 65.75% 16.85% -70.36%
Accrued Expenses $21.10M $21.27M $28.80M
YoY Change 7.97% -26.15% -50.11%
Deferred Revenue $42.00K $42.00K $89.00K
YoY Change -28.81% -52.81% -79.91%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $69.54M $37.67M $40.58M
YoY Change 153.89% -7.19% -52.61%
LONG-TERM LIABILITIES
Long-Term Debt $80.40M $128.6M $127.1M
YoY Change -36.91% 1.17% -19.96%
Other Long-Term Liabilities $3.567M $4.318M $5.537M
YoY Change -31.68% -22.02% -62.48%
Total Long-Term Liabilities $3.567M $4.318M $5.537M
YoY Change -31.68% -22.02% -62.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.54M $37.67M $40.58M
Total Long-Term Liabilities $3.567M $4.318M $5.537M
Total Liabilities $153.5M $170.6M $173.2M
YoY Change -4.1% -1.53% -33.27%
SHAREHOLDERS EQUITY
Retained Earnings -$935.5M -$862.1M -$808.0M
YoY Change 15.05% 6.7% 23.91%
Common Stock $835.8M $760.3M $731.0M
YoY Change 13.76% 4.01% 37.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$118.8M -$120.9M -$96.11M
YoY Change
Total Liabilities & Shareholders Equity $34.70M $49.67M $77.10M
YoY Change -44.58% -35.57% -35.72%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$73.45M -$17.81M -$5.513M
YoY Change 1336.33% 223.0% -92.98%
Depreciation, Depletion And Amortization $100.0K $200.0K $200.0K
YoY Change -50.0% 0.0% -60.0%
Cash From Operating Activities -$11.03M -$11.62M -$19.64M
YoY Change 12.49% -40.82% -44.97%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $20.00K -$214.0K
YoY Change -100.0% -109.35% -45.13%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.000K $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$19.00K -$214.0K
YoY Change -100.0% -91.12% -61.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.850M 7.630M 1.125M
YoY Change 92.96% 578.22% -97.0%
NET CHANGE
Cash From Operating Activities -11.03M -11.62M -19.64M
Cash From Investing Activities 0.000 -19.00K -214.0K
Cash From Financing Activities -2.850M 7.630M 1.125M
Net Change In Cash -13.88M -4.011M -18.73M
YoY Change 21.27% -78.58% -1573.49%
FREE CASH FLOW
Cash From Operating Activities -$11.03M -$11.62M -$19.64M
Capital Expenditures $0.00 $20.00K -$214.0K
Free Cash Flow -$11.03M -$11.64M -$19.43M
YoY Change 14.41% -40.07% -44.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.01
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001580063
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://bioratherapeutics.com/20230630#AccruedExpensesAndOtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39334
dei Entity Registrant Name
EntityRegistrantName
Biora Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3950390
dei Entity Address Address Line1
EntityAddressAddressLine1
4330 La Jolla Village Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
727-2841
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BIOR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13883762
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26452000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000
CY2023Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
819000
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
828000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4105000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4199000
CY2023Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
2509000
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
2603000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
33885000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38116000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1351000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1654000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1887000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1482000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6478000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6201000
CY2023Q2 us-gaap Goodwill
Goodwill
6072000
CY2022Q4 us-gaap Goodwill
Goodwill
6072000
CY2023Q2 us-gaap Assets
Assets
49673000
CY2022Q4 us-gaap Assets
Assets
53525000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5042000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3606000
CY2023Q2 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21791000
CY2022Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16161000
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
10835000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3538000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
37668000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23305000
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
128568000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
127811000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4318000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4696000
CY2023Q2 us-gaap Liabilities
Liabilities
170554000
CY2022Q4 us-gaap Liabilities
Liabilities
155812000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
164000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
164000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13686964
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9098844
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13420859
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8928498
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
760277000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
743626000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-862091000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-826843000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
266105
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
170346
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19078000
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.81
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.01
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19078000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-120881000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102287000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49673000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53525000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
211000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5983000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5904000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13173000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12462000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8953000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8410000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17309000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21867000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
14936000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
14314000
us-gaap Operating Expenses
OperatingExpenses
30482000
us-gaap Operating Expenses
OperatingExpenses
34329000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14934000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14210000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30478000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34118000
CY2023Q2 us-gaap Interest Expense
InterestExpense
2703000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2772000
us-gaap Interest Expense
InterestExpense
5383000
us-gaap Interest Expense
InterestExpense
5532000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
161000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4413000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-703000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13402000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5735000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-86000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4924000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17803000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6834000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35244000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21324000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-837000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-837000
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-17807000
CY2022Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5997000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-35248000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-20487000
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
484000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1166000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17807000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5513000
us-gaap Net Income Loss
NetIncomeLoss
-35248000
us-gaap Net Income Loss
NetIncomeLoss
-19321000
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.47
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.47
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.81
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-96106000
us-gaap Net Income Loss
NetIncomeLoss
-35248000
us-gaap Net Income Loss
NetIncomeLoss
-19321000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1166000
bior Non Cash Revenue Reserve
NonCashRevenueReserve
0
bior Non Cash Revenue Reserve
NonCashRevenueReserve
201000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.79
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.79
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.06
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.06
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.16
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12143108
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12143108
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7374865
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7374865
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11718408
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11718408
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7351595
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7351595
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102287000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12524000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-178000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2384000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17441000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-104998000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-90000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2014000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17807000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-120881000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-84976000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3626000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-80000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2053000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13808000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-93185000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1168000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
89000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-111000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1446000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5513000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
313000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
547000
us-gaap Share Based Compensation
ShareBasedCompensation
4398000
us-gaap Share Based Compensation
ShareBasedCompensation
3499000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
757000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
694000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-320000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
100000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
-545000
us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Gain Loss On Investments
GainLossOnInvestments
5731000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-703000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13402000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-10000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
817000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
59000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
904000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1437000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4434000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6170000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4486000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-904000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-958000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-23720000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-45413000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
1819000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23720000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43594000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
556000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-556000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12883000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4794000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
89000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
484000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
688000
bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
612000
bior Principal Payments On Capital Lease Obligations
PrincipalPaymentsOnCapitalLeaseObligations
0
bior Principal Payments On Capital Lease Obligations
PrincipalPaymentsOnCapitalLeaseObligations
12000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19711000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4259000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4034000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39891000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88397000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26452000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48506000
us-gaap Interest Paid Net
InterestPaidNet
1059000
us-gaap Interest Paid Net
InterestPaidNet
4811000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
17000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1133000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2922000
bior Enumera Molecular Investment In Exchange For Assets
EnumeraMolecularInvestmentInExchangeForAssets
0
bior Enumera Molecular Investment In Exchange For Assets
EnumeraMolecularInvestmentInExchangeForAssets
6000000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
40000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22700000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
3800000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-862100000
us-gaap Net Income Loss
NetIncomeLoss
-35200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the valuation of stock options, the valuation of goodwill, accrual for reimbursement claims and settlements, the valuation of warrant liabilities, the valuation of assets held for sale, assessing future tax exposure and the realization of deferred tax assets, and the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p>
CY2023Q2 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
3800000
CY2022Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
0
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
0
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
759000
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
2027000
CY2022Q2 bior Disposal Group Including Discontinued Operation Selling General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense
275000
bior Disposal Group Including Discontinued Operation Selling General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense
861000
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
275000
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
861000
CY2022Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
484000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1166000
CY2022Q2 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
500000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1900000
CY2022Q4 bior Accrued Interest Current
AccruedInterestCurrent
890000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
810000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
893000
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1517000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3912000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3634000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
193000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
565000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4105000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4199000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3750000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5653000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2399000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3999000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1351000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1654000
CY2023Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
300000
CY2022Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
CY2023Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
478000
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
201000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6478000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6201000
CY2023Q2 bior Accrual For Reimbursement Claims And Settlements Current
AccrualForReimbursementClaimsAndSettlementsCurrent
8472000
CY2022Q4 bior Accrual For Reimbursement Claims And Settlements Current
AccrualForReimbursementClaimsAndSettlementsCurrent
8372000
CY2023Q2 bior Commission And Bonus Current
CommissionAndBonusCurrent
1351000
CY2022Q4 bior Commission And Bonus Current
CommissionAndBonusCurrent
1433000
CY2023Q2 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1353000
CY2022Q4 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1724000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
817000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
307000
CY2023Q2 bior Accrued Interest Current
AccruedInterestCurrent
4687000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
445000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
42000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
47000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2742000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2050000
CY2023Q2 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21791000
CY2022Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16161000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1127000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
601000
CY2023Q2 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
3191000
CY2022Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
4095000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4318000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4696000
CY2023Q2 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q2 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
128600000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
127800000
CY2023Q2 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
73100000
CY2022Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
71800000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4200000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4900000
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.30
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3018868
CY2023Q2 bior Common Stock Ownership Percentage
CommonStockOwnershipPercentage
0.05
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
400
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
400
us-gaap Operating Lease Cost
OperatingLeaseCost
800
us-gaap Operating Lease Cost
OperatingLeaseCost
700
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
497000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
938000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
507000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
215000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
18000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2175000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
238000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1937000
CY2020Q3 bior Number Of States Participating In Settlement
NumberOfStatesParticipatingInSettlement
45
CY2020Q4 bior Aggregate Amount Of Historical Payments
AggregateAmountOfHistoricalPayments
27400000
CY2023Q2 bior Payor Recoupment
PayorRecoupment
1100000
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On January 3, 2023, the Company effected a 1-for-25 reverse stock split of the Company's common stock.
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
77280
bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
13400000
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1300250
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9000000.0
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6000000.0
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1600000
CY2022Q4 bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
800000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
900000
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
5.30
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3018868
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.05
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7300000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000.0
bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
1000000.0
bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
700000
CY2023Q2 bior Remeasurement Of Warrant Liability
RemeasurementOfWarrantLiability
6900000
CY2023Q2 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
2100000
CY2022Q4 bior Number Of Vote Per Preferred Stock Held
NumberOfVotePerPreferredStockHeld
3000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
582557
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
59.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
187400
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20297
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
42.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
40928
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
110.06
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
708732
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
49000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
708732
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
42.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
49000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
230465
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
78.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.040
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.020
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.907
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.53
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2014000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1446000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4398000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3499000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8804945
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3574315

Files In Submission

Name View Source Status
bior-20230630_def.xml Edgar Link unprocessable
0000950170-23-042476-index-headers.html Edgar Link pending
0000950170-23-042476-index.html Edgar Link pending
0000950170-23-042476.txt Edgar Link pending
0000950170-23-042476-xbrl.zip Edgar Link pending
bior-20230630.htm Edgar Link pending
bior-20230630.xsd Edgar Link pending
bior-ex31_1.htm Edgar Link pending
bior-ex31_2.htm Edgar Link pending
bior-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
bior-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bior-20230630_pre.xml Edgar Link unprocessable
bior-20230630_lab.xml Edgar Link unprocessable
bior-20230630_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending